In this instalment of Robert Macneill’s (Covance) column, Robert explores the potential information to be gleaned from calibration curves and how these insights could possibly fuel innovation in the field of biomarker quantification.
Browsing: Expert columns
A rapid mobile-based assay for determination of inflammation through quantification of alpha-1-acid glycoprotein has been developed.
In this installment of Robert MacNeill’s (Covance) column, Robert discusses the potential disparity in results when using a given method for extracted analytical batches versus in solution, the different challenges involved with solutions and extracts and the necessity to fully consider the relevant chemistry from the earliest stages of method development.
Brexit or no Brexit? The question that has been weighing on the UK for the past 3 years will soon have an answer (hopefully). Read this commentary from Zamas Lam (QPS; DE, USA) discussing how Brexit relates to the future of drug discovery, preclinical and clinical drug development.
In this installment of Robert MacNeill’s (Covance) column, Robert discusses where to best place specific QC samples within a calibration range for a methodology, and the challenges associated with establishing suitable nominal levels for the internal standard concentration.
With the reality of Brexit already impacting the UK’s clinical trials environment, Zamas Lam (QPS; DE, USA) discusses the effect this will have on bioanalytical research, and suggests 10 questions to ask when relocating UK-based preclinical and bioanalysis research projects.
In this installment of Robert MacNeill’s (Envigo) column, Robert discusses methodologies for small lipids, and why these can be a particularly challenging area of biologics.
“There are, in essence, two schools of thought that I can perceive when discussions occur on the topic of appropriate purity of the laboratory water and various solvents, additives and reagents for any given stage of a quantitative bioanalytical procedure.” Find out more from Robert MacNeill (Envigo) in this editorial column.
In this editorial, Robert MacNeill (Envigo) dicusses the case for the surrogate analyte approach for biomarker validation.
Read time: 3 mins
In this installment, Robert discusses how to get to grips with metabolites; the ways in which metabolites may affect the performance and reliability of an assay, and what could be done to overcome them.